Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05 2023 - 4:30PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
committed to advancing new standards of care for the frontline
treatment of hematologic malignancies, today announced the grant of
a restricted stock unit (RSU) award for 9,000 shares of Syros
common stock to one newly hired employee in connection with
commencing employment with Syros. This RSU was granted as a
material inducement to employment in accordance with Nasdaq Listing
Rule 5635(c)(4).
The award was granted on June 30, 2023, and vests as to
one-quarter of the shares on June 30, 2024, and as to an additional
one-quarter of the shares at the end of each successive year
thereafter, subject to the employee’s continued service with Syros.
This award is subject to the terms and conditions of a restricted
stock unit agreement covering the award and Syros’ 2022 Inducement
Stock Incentive Plan.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the
frontline treatment of patients with hematologic malignancies.
Driven by the motivation to help patients with blood disorders that
have largely eluded other targeted approaches, Syros is advancing a
robust late-stage clinical pipeline, including tamibarotene, an
oral selective RARα agonist in patients with higher-risk
myelodysplastic syndrome and acute myeloid leukemia with RARA gene
overexpression, and SY-2101, a novel oral form of arsenic trioxide
in patients with acute promyelocytic leukemia. Syros is also
seeking partnerships for SY-5609, a highly selective and potent
CDK7 inhibitor in clinical development for the treatment of select
solid tumors, and multiple preclinical programs in oncology. For
more information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230705495927/en/
Syros Contact Karen Hunady Director of Corporate
Communications & Investor Relations 1-857-327-7321
khunady@syros.com
Investor Contact Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From May 2023 to May 2024